IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate

Xanthe A. M. H. van Dierendonck, Kyra E. de Goede, Jan van den Bossche*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Isocitrate dehydrogenase (IDH) mutations produce high levels of the ‘oncometabolite’ R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain. A recent study in Nature Cancer by Friedrich et al. describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages. As such, the authors uncovered a new vulnerability that can be exploited for therapy.
Original languageEnglish
Pages (from-to)666-667
Number of pages2
JournalTrends in cancer
Volume7
Issue number8
Early online date2021
DOIs
Publication statusE-pub ahead of print - 2021

Cite this